Please login to the form below

Not currently logged in
Email:
Password:

Tcelna

This page shows the latest Tcelna news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA drops Ono-partnered multiple sclerosis drug

Merck KGaA drops Ono-partnered multiple sclerosis drug

It also has a licensing deal in place for Tcelna (imilecleucel-T), a personalised treatment for secondary-progressive MS developed by Opexa Therapeutics that is in phase IIb testing with

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2013 Pharma deals during February 2013

    sales. In the other option deal, Merck Serono has acquired an option over Opexa Therapeutics' phase IIb Tcelna (imilecleucel-T) vaccine for MS (for all territories except Japan). ... Tcelna is being developed as a personalised therapy specifically

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics